Company Performance Metrics
IMIWN develops biotechnology solutions focused on soluble Toll-like receptor 2 as a biomarker of sepsis and other inflammatory conditions. The company designs and supplies the imiwn sTLR2 RAPID lateral flow assay for semi-quantitative measurement of human sTLR2 in plasma, serum, and whole blood. It also offers a proprietary portfolio of monoclonal
and polyclonal anti-human sTLR2 antibodies, including antibody pairs, for research and commercial assay development. IMIWN supports use of its diagnostic test kits in clinical laboratories where UKCA certified and in research settings elsewhere under investigational use. Its scientific content, instructions for use, and validation data help clinicians and immunology researchers apply sTLR2 measurement in early sepsis assessment and broader inflammation studies.
